Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 17/20 | 0.59 |
| ▸ | TTK | P33981 | 3/20 | 0.58 |
| ▸ | PLK3 | Q9H4B4 | 7/20 | 0.58 |
| ▸ | PLK2 | Q9NYY3 | 5/20 | 0.58 |
| ▸ | FLT3 | P36888 | 5/20 | 0.58 |
| ▸ | NEK6 | Q9HC98 | 3/20 | 0.58 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.56 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.56 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.56 |
| ▸ | MELK | Q14680 | 1/20 | 0.56 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.56 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.55 |
| ▸ | CDK2 | P24941 | 2/20 | 0.55 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.55 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.54 |
| ▸ | PIM1 | P11309 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL526080 | 0.91 | TTK (0.69) | PLK1TTKPLK3PLK2CSNK2A2 | |
| SCHEMBL10092916 | 0.90 | PLK1 (0.68) | PLK1TTKPLK3PLK2FLT3 | |
| SCHEMBL10092918 | 0.90 | PLK1 (0.67) | PLK1TTKPLK3PLK2FLT3 | |
| SCHEMBL525963 | 0.90 | PLK1 (0.59) | PLK1TTKPLK3PLK2FLT3 | |
| SCHEMBL1558606 | 0.87 | PLK1 (0.75) | PLK1TTKPLK3PLK2FLT3 | |
| SCHEMBL525981 | 0.86 | TTK (0.79) | PLK1TTKPLK3PLK2FLT3 | |
| SCHEMBL527318 | 0.85 | TTK (0.68) | PLK1TTKPLK3PLK2FLT3 | |
| SCHEMBL525992 | 0.84 | CDK2 (0.59) | TTKCCNA2CDK2CCNA1PIM1 | |
| SCHEMBL10092911 | 0.83 | PLK1 (0.67) | PLK1TTKPLK3PLK2FLT3 | |
| SCHEMBL10092912 | 0.83 | PLK1 (0.68) | PLK1TTKPLK3PLK2FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9333205-B2 | Isoxazolo-quinazolines as modulators of protein kinase activity | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-05-10 | — | — | US | disclosed |
| US-9333205-B2 | Isoxazolo-quinazolines as modulators of protein kinase activity | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-05-10 | — | — | US | disclosed |
| US-9333205-B2 | Isoxazolo-quinazolines as modulators of protein kinase activity | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-05-10 | — | — | US | disclosed |
| EP-2598508-B1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-04-22 | — | — | EP | disclosed |
| EP-2598508-B1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-04-22 | — | — | EP | disclosed |
| US-20130143896-A1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-06-06 | — | — | US | disclosed |
| US-20130143896-A1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-06-06 | — | — | US | disclosed |
| US-20130143896-A1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-06-06 | — | — | US | disclosed |
| EP-2598508-A1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | Nerviano Medical Sciences S.r.l. (IT) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012013557-A1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143896-A1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | CSNK1A1, RPS6KA1, CSNK2A1 | PLK1 183/4885TTK 341/4885PLK3 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.